Blood transfusions may be challenging in children with cold agglutinin disease (CAD), but should remain an option for those with severe disease, a small study in India suggests. Most of the eight children with CAD in the study received a blood transfusion, but none were complete matches in terms…
News
Enrollment for a Phase 1b basket clinical trial of povetacicept (ALPN-303), an experimental anti-inflammatory therapy, for adults with cold agglutinin disease (CAD) and other autoimmune cytopenias is expected to start in the coming months. That’s according to a corporate update from the treatment’s developer, Alpine Immune Sciences. Basket…
A treatment to reduce the activation of the immune complement system didn’t increase the effectiveness of red blood cell transfusions in people with severe cold agglutinin disease (CAD) and other complement-mediated autoimmune hemolytic anemia (CM-AIHA). That’s according to a small, proof-of-concept Phase 2 clinical trial (EudraCT2012-003710-13) that found…
A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…
The rare case of a young woman with cold agglutinin disease (CAD) secondary to chickenpox, also known as varicella, was described in a recent report in India. While corticosteroids, a type of steroid, are usually not recommended for CAD secondary to an infection, the rapid and sustained red blood…
Enrollment is underway in a Phase 3 clinical trial testing the investigational therapy pegcetacoplan in adults with primary cold agglutinin disease (CAD), according to a corporate update from the treatment’s developer, Apellis Pharmaceuticals. The trial, called CASCADE (NCT05096403), is enrolling up to 57 patients, 18…
Signs of cold agglutinin disease (CAD) — later found to have been triggered by a previous COVID-19 infection — were detected during heart surgery in a man in Turkey, a case study showed. The case adds to several others reporting developing CAD following COVID-19 disease. Despite being rare,…
Splenectomy, or the surgical removal of the spleen, significantly reduced unmanageable red blood cell destruction in a man with primary cold agglutinin disease (CAD), a study showed. While this approach is usually considered to be ineffective in CAD patients, this case report adds to other studies where CAD was successfully…
Fetal complications are about four times more common in pregnant women with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), than in those without the autoimmune condition, according to a small study. Still, maternal complications occurred at similar rates, and most were directly linked to AIHA relapses, or…
Note: This story was updated Jan. 30, 2023, to correct that the CARDINAL trial did not include a placebo group. The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of…
Recent Posts
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD
- With my health from CAD steadily declining, I call in the cavalry, part 2
- FDA fast-tracks potential new option for autoimmune blood diseases
- Long-term Enjaymo use shows favorable outcomes in CAD: Study
- With my health from CAD steadily declining, I call in the cavalry, part 1
- Genetic variations in underlying lymphoma influence AIHA types
- Lessons from ‘Winnie-the-Pooh’ help me navigate life with CAD